



Sheet 1 of 1

RECEIVED
NOV 05 2003
TECH CENTER 1600/2900

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01379K	SERIAL NO.: 10/057,640
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Harry R. Davis, et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SW	AA	5,021,461	06/04/91	Robinson et al.			
SW	AB	4,687,777	08/18/87	Meguro et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SW	AC	WO 97/28149	08/07/97	PCT				
	AD	WO 99/22728	05/14/99	PCT				
	AE	WO 01/96347	12/20/01	PCT				
	AF	WO 02/26729	04/04/02	PCT				
	AG	WO 02/064094	08/22/02	PCT				
	AH	WO 95/35277	12/28/95	PCT				
	AI	WO 02/50027	06/27/02	PCT				
	AJ	WO 02/50060	06/27/02	PCT				
	AK	WO 02/50068	06/27/02	PCT				
	AL	WO 99/08501	02/25/99	PCT				
	AM	WO 94/26738	11/24/94	PCT				
	AN	EP 1 036 563 A1	09/20/00	EPO				
	AO	EP 0 753 298 A1	01/15/97	EPO				
SW	AP	FR 1103113	10/31/55	FRANCE			X (abs.)	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SW	AQ	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)
	AR	Gilbert R. Thompson et al., Novel lipid-regulating drugs, <i>Exp. Opin. Invest. Drugs</i> 9(11):2619-2628 (2000)
	AS	T. Kosoglou et al., Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects on Apo CIII and LDL Subfractions, <i>Atherosclerosis</i> 2:89 (2001)
	AT	Harry R. Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, <i>Metabolism</i> 50 (10):1234-1241 (2001)
	AU	Study Showed Ezetimibe Significantly Reduced Levels of LDL Cholesterol or "Bad" Cholesterol in Patients, Schering-Plough Press Release
	AV	T. Kosoglou et al., Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe, <i>Atherosclerosis</i> (2):38 (2001)
	AW	Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647
	AX	Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982)
SW	AY	R. Milanese et al., Xantom E Ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)

EXAMINER S. Wang	DATE CONSIDERED 12/09/02
-------------------------	---------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01379K

APPLICATION NO.:

10/247,646

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

HARRY R. DAVIS et al.

FILING DATE:

01/25/2002

GROUP:

1614

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SW	AQ	T. Kosoglou et al., "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 rd International Congress on Coronary, Artery Disease from Prevention to Intervention, Lyon, France p. 71 (2000), XP008027568						
	AR							
	AS							
	AT							
	AU							
	AV							

EXAMINER

S. Wang

DATE CONSIDERED

12/8/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.